Stockscreener 앱 받기
8.78
5.02%
0.42
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Yahoo Finance
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics (KYTX) Stock Analysis Report | Financials & Insights - Benzinga
Octaware Technologies Limited Added to High Probability Setup ListEvening Star Patterns & Free Navigate Market With Precision - earlytimes.in
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
6 Companies Hanging On in Cell Therapy - BioSpace
Kyverna Therapeutics Inc Stock Analysis and ForecastInflation Impact on Stocks & Breakout Portfolio Performance - earlytimes.in
Aug Gainers: What margin trends mean for Kyverna Therapeutics Inc. stock2025 Key Lessons & Real-Time Chart Pattern Alerts - moha.gov.vn
FY2025 Earnings Estimate for KYTX Issued By HC Wainwright - MarketBeat
Trend Recap: Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases - TipRanks
Why Kyverna Therapeutics Inc. stock remains resilient2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
How sentiment analysis helps forecast Kyverna Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsWeekly Profit Summary & Verified Entry Point Signals - newser.com
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX) - Seeking Alpha
KYTX: KYV-101 delivers transformative results in autoimmune diseases, targeting first-to-market leadership - TradingView
KYTX: KYV101 demonstrates transformative efficacy and safety in autoimmune diseases, targeting first-to-market leadership - TradingView
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
What analysts say about Kyverna Therapeutics Inc stockVWAP Trading Strategies & Calculate Profit Targets With AI Accuracy - earlytimes.in
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
1.08%
0.91%
자본화:
|
볼륨(24시간):